Arepanrix is named as an intervention in 2 current clinical trials in our Canada register. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is University Health Network, Toronto (1). The most-studied condition is Avian Influenza.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
NCT07240558 · ClinicalTrials.gov ↗ · Influenza (Pandemic), Avian Influenza, Vaccination
|
Phase 3 | Recruiting | University Health Network, Toronto | Canada |
|
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
NCT07275060 · ClinicalTrials.gov ↗ · H5N1 Influenza, H5N1 Virus, Avian Influenza
|
Phase 4 | Active, closed | Canadian Immunization Research Network | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| University Health Network, Toronto | 1 |
| Canadian Immunization Research Network | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada register name Arepanrix (also registered as H5N1 vaccine) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University Health Network, Toronto (1) and Canadian Immunization Research Network (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Arepanrix works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Arepanrix works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Arepanrix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.